Observational Study
Copyright ©The Author(s) 2023.
World J Psychiatry. May 19, 2023; 13(5): 226-233
Published online May 19, 2023. doi: 10.5498/wjp.v13.i5.226
Table 1 Clinical characteristics of patients in two groups, n (%)
Clinical characteristics
Observation group
Control group
t/χ2
P value
Patients9595--
Age (yr)64.4 ± 9.463.0 ± 9.21.0520.294
Male55 (57.9)49 (51.6)0.7650.382
Depressive course (d)50.8 ± 15.347.5 ± 13.41.5790.116
Smoking history38 (40.0)31 (32.6)1.1150.291
Diabetes course (yr)6.2 ± 3.65.7 ± 3.20.9410.348
History of hypertension52 (54.7)46 (48.4)0.7590.384
History of coronary heart disease37 (38.9)32 (33.7)0.5690.451
History of hyperlipidemia63 (66.3)52 (54.7)2.6660.103
Body mass index (kg/m2)25.8 ± 3.826.2 ± 4.1-0.6760.500
Systolic blood pressure (mmHg)139.2 ± 13.3137.6 ± 12.30.8730.384
Stroke type1.7240.189
Ischemic stroke57 (60.0)48 (50.5)
Hemorrhagic stroke38 (40.0)47 (49.5)
Table 2 Depressive state and neurological function scores of the two groups
Group
Patients
MADRS scores
NIHSS scores
Before treatment
After treatment
Before treatment
After treatment
Observation group9533.7 ± 5.014.3 ± 5.2a,d21.9 ± 4.112.2 ± 4.0a,d
Control group9533.0 ± 4.018.1 ± 3.5a21.0 ± 3.916.1 ± 3.4a
Table 3 The levels of hypersensitive C-reactive protein and tumor necrosis factor-α in the two groups
Group
Patients
Hypersensitive C-reactive protein (mg/L)
Tumor necrosis factor-α (ng/L)
Before treatment
After treatment
Before treatment
After treatment
Observation group957.71 ± 1.732.87 ± 1.49a,d57.2 ± 13.626.7 ± 12.5a,d
Control group957.43 ± 1.534.52 ± 1.42a58.6 ± 11.933.9 ± 11.1a
Table 4 Fasting blood glucose levels of the two groups
Group
Patients
Before treatment
After treatment
t value
P value
Observation group9510.96 ± 0.918.02 ± 1.1020.177< 0.001
Control group9511.16 ± 0.939.26 ± 1.0413.256< 0.001
t value--1.475-7.994--
P value-0.142< 0.001--